{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:13:57Z","timestamp":1793121237133,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>Background<\/jats:italic> Immune-related hepatotoxicity is often regarded as immune-related hepatitis (irHepatitis) despite including immune-related sclerosing cholangitis (irSC). This study examined the clinical differences between irSC and irHepatitis. <jats:italic>Methods<\/jats:italic> A single-center retrospective study of 530 consecutive patients who received immunotherapy between August 2014 and April 2020 was performed. IrSC and irHepatitis were respectively defined as the radiological presence and absence of bile duct dilation and wall thickness. <jats:italic>Results<\/jats:italic> Forty-one patients (7.7%) developed immune-related hepatotoxicity. A CT scan was performed on 12 patients, including 11 of 12 with\u2009\u2265\u2009grade 3 aminotransferase elevations. IrSC and irHepatitis were diagnosed in 4 (0.8%) and 8 (1.5%) patients, respectively. All the irSC patients had been treated with anti-PD-1. IrHepatitis was more common among patients receiving anti-CTLA-4 than among those receiving anti-PD-1\/PD-L1 inhibitors (14%, 7\/50 vs. 0.2%, 1\/480, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). A\u2009\u2265\u2009grade 2 alkaline phosphatase (ALP) elevation resulting in a cholestatic pattern was seen in all 4 irSC patients. Among the irSC patients, 3 (3\/4, 75%) developed\u2009\u2265\u2009grade 3 aminotransferases elevation. The median duration from the start of immunotherapy until\u2009\u2265\u2009grade 2 liver enzymes elevation was 257 and 55.5\u00a0days in irSC and irHepatitis patients. The median times for progression from grade 2 to 3 liver enzyme elevation were 17.5 and 0\u00a0days, respectively. <jats:italic>Conclusions<\/jats:italic> IrSC and irHepatitis have different characteristics in the class of immune checkpoint inhibitor and onset pattern. Radiological examination for the diagnosis of irSC should be considered for patients with\u2009\u2265\u2009grade 2 ALP elevation resulting in a cholestatic pattern. (Registration number J2020-36, Date of registration June 3, 2020)<\/jats:p>","DOI":"10.1007\/s10637-021-01136-z","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T01:02:56Z","timestamp":1622163776000},"page":"1716-1723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3693-5540","authenticated-orcid":false,"given":"Masaki","family":"Takinami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5705-9423","authenticated-orcid":false,"given":"Akira","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Mamesaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Wakuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kiyohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Niwakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"1136_CR1","unstructured":"Squibb BM (2019) Yervoy (ipilimumab)[package insert]. US Food and Drug Administration website"},{"key":"1136_CR2","doi-asserted-by":"publisher","unstructured":"Danan G, Teschke R (2015) RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci 17. https:\/\/doi.org\/10.3390\/ijms17010014","DOI":"10.3390\/ijms17010014"},{"key":"1136_CR3","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.jhep.2018.08.014","volume":"69","author":"L Parlati","year":"2018","unstructured":"Parlati L, Vallet-Pichard A, Batista R, Hernvann A, Sogni P, Pol S, Mallet V, group C, (2018) Incidence of grade 3\u20134 liver injury under immune checkpoints inhibitors: A retrospective study. J Hepatol 69:1396\u20131397. https:\/\/doi.org\/10.1016\/j.jhep.2018.08.014","journal-title":"J Hepatol"},{"key":"1136_CR4","doi-asserted-by":"publisher","unstructured":"Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, Committee EG (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119-iv42. https:\/\/doi.org\/10.1093\/annonc\/mdx225","DOI":"10.1093\/annonc\/mdx225"},{"key":"1136_CR5","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ et al (2018) Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"1136_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/annonc\/mdw649","volume":"28","author":"F Gelsomino","year":"2017","unstructured":"Gelsomino F, Vitale G, D\u2019Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28:671\u2013672. https:\/\/doi.org\/10.1093\/annonc\/mdw649","journal-title":"Ann Oncol"},{"key":"1136_CR7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K, Haratani K, Hayashi H et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529\u2013536. https:\/\/doi.org\/10.1007\/s10637-017-0453-0","journal-title":"Invest New Drugs"},{"key":"1136_CR8","doi-asserted-by":"publisher","unstructured":"Lindor KD, Kowdley KV, Harrison ME, American College of G (2015) ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 110:646\u2013659; quiz 60. https:\/\/doi.org\/10.1038\/ajg.2015.112","DOI":"10.1038\/ajg.2015.112"},{"key":"1136_CR9","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s00534-012-0521-y","volume":"19","author":"H Ohara","year":"2012","unstructured":"Ohara H, Okazaki K, Tsubouchi H, Inui K, Kawa SH et al (2012) Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci 19:536\u2013542. https:\/\/doi.org\/10.1007\/s00534-012-0521-y","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1136_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1148\/rg.244035719","volume":"24","author":"KJ Mortele","year":"2004","unstructured":"Mortele KJ, Segatto E, Ros PR (2004) The infected liver: radiologic-pathologic correlation. Radiographics 24:937\u2013955. https:\/\/doi.org\/10.1148\/rg.244035719","journal-title":"Radiographics"},{"key":"1136_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3748\/wjg.v26.i3.353","volume":"26","author":"T Onoyama","year":"2020","unstructured":"Onoyama T, Takeda Y, Yamashita T, Hamamoto W, Sakamoto Y, Koda H, Kawata S, Matsumoto K, Isomoto H (2020) Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review. World J Gastroenterol 26:353\u2013365. https:\/\/doi.org\/10.3748\/wjg.v26.i3.353","journal-title":"World J Gastroenterol"},{"key":"1136_CR12","unstructured":"Institute NC (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. In: National Cancer Institute"},{"key":"1136_CR13","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/apt.15413","volume":"50","author":"I Tsung","year":"2019","unstructured":"Tsung I, Dolan R, Lao CD, Fecher L, Riggenbach K, Yeboah-Korang A, Fontana RJ (2019) Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Aliment Pharmacol Ther 50:800\u2013808. https:\/\/doi.org\/10.1111\/apt.15413","journal-title":"Aliment Pharmacol Ther"},{"key":"1136_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"1136_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa201","author":"M Takinami","year":"2020","unstructured":"Takinami M, Ono A, Moriguchi M, Takahashi T (2020) Pembrolizumab-related sclerosing cholangitis manifested by a pruned-tree appearance of the bile ducts. Jpn J Clin Oncol. https:\/\/doi.org\/10.1093\/jjco\/hyaa201","journal-title":"Jpn J Clin Oncol"},{"key":"1136_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31227","author":"TB Peeraphatdit","year":"2020","unstructured":"Peeraphatdit TB, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR (2020) Hepatotoxicity from Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. Hepatology. https:\/\/doi.org\/10.1002\/hep.31227","journal-title":"Hepatology"},{"key":"1136_CR17","unstructured":"Squibb BM (2019) Opdivo (Nivolumab) [Package Insert]. Princeton, NJ"},{"key":"1136_CR18","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","volume":"68","author":"E De Martin","year":"2018","unstructured":"De Martin E, Michot JM, Papouin B, Champiat S, Mateus C et al (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol 68:1181\u20131190. https:\/\/doi.org\/10.1016\/j.jhep.2018.01.033","journal-title":"J Hepatol"},{"key":"1136_CR19","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","volume":"39","author":"M Johncilla","year":"2015","unstructured":"Johncilla M, Misdraji J, Pratt DS, Agoston AT, Lauwers GY, Srivastava A, Doyle LA (2015) Ipilimumab-associated Hepatitis: Clinicopathologic Characterization in a Series of 11 Cases. Am J Surg Pathol 39:1075\u20131084. https:\/\/doi.org\/10.1097\/PAS.0000000000000453","journal-title":"Am J Surg Pathol"},{"key":"1136_CR20","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1053\/JTLS005s00021","volume":"5","author":"KP Batts","year":"1999","unstructured":"Batts KP (1999) Acute and chronic hepatic allograft rejection: pathology and classification. Liver Transpl Surg 5:S21\u2013S29. https:\/\/doi.org\/10.1053\/JTLS005s00021","journal-title":"Liver Transpl Surg"},{"key":"1136_CR21","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1111\/j.1600-6143.2008.02300.x","volume":"8","author":"W Li","year":"2008","unstructured":"Li W, Kuhr CS, Zheng XX, Carper K, Thomson AW, Reyes JD, Perkins JD (2008) New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells. Am J Transplant 8:1639\u20131651. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02300.x","journal-title":"Am J Transplant"},{"key":"1136_CR22","doi-asserted-by":"publisher","first-page":"e109866","DOI":"10.1371\/journal.pone.0109866","volume":"9","author":"K Higashikawa","year":"2014","unstructured":"Higashikawa K, Yagi K, Watanabe K, Kamino S, Ueda M, Hiromura M, Enomoto S (2014) 64Cu-DOTA-anti-CTLA-4 mAb enabled PET visualization of CTLA-4 on the T-cell infiltrating tumor tissues. PLoS One 9:e109866. https:\/\/doi.org\/10.1371\/journal.pone.0109866","journal-title":"PLoS ONE"},{"key":"1136_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jhep.2014.04.027","volume":"61","author":"A Carambia","year":"2014","unstructured":"Carambia A, Freund B, Schwinge D, Heine M, Laschtowitz A et al (2014) TGF-beta-dependent induction of CD4(+)CD25(+)Foxp3(+) Tregs by liver sinusoidal endothelial cells. J Hepatol 61:594\u2013599. https:\/\/doi.org\/10.1016\/j.jhep.2014.04.027","journal-title":"J Hepatol"},{"key":"1136_CR24","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/his.14000","volume":"76","author":"Y Zen","year":"2020","unstructured":"Zen Y, Chen YY, Jeng YM, Tsai HW, Yeh MM (2020) Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes. Histopathology 76:470\u2013480. https:\/\/doi.org\/10.1111\/his.14000","journal-title":"Histopathology"},{"key":"1136_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jhep.2019.05.023","volume":"71","author":"G Ravichandran","year":"2019","unstructured":"Ravichandran G, Neumann K, Berkhout LK, Weidemann S, Langeneckert AE et al (2019) Interferon-gamma-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice. J Hepatol 71:773\u2013782. https:\/\/doi.org\/10.1016\/j.jhep.2019.05.023","journal-title":"J Hepatol"},{"key":"1136_CR26","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/hep.31089","volume":"71","author":"L Stuart","year":"2020","unstructured":"Stuart L, Lambourne B, Turner P, Jones DEJ, Plummer R, Cresti N, Dyson JK (2020) Pembrolizumab as a Cause of Cholangiopathy in a Patient With Metastatic Melanoma. Hepatology 71:2164\u20132166. https:\/\/doi.org\/10.1002\/hep.31089","journal-title":"Hepatology"},{"key":"1136_CR27","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","volume":"2","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Sullivan RJ, Ott PA, Carlino MS, Khushalani NI et al (2016) Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncol 2:234\u2013240. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4368","journal-title":"JAMA Oncol"},{"key":"1136_CR28","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368\u2013376. https:\/\/doi.org\/10.1093\/annonc\/mdw443","journal-title":"Ann Oncol"},{"key":"1136_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","volume":"32","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, Rochon J, Group DS (2009) Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 32:55\u201368. https:\/\/doi.org\/10.2165\/00002018-200932010-00005","journal-title":"Drug Saf"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01136-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01136-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01136-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:35:18Z","timestamp":1678509318000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01136-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01136-z","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"assertion":[{"value":"17 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of institutional Review Board of Shizuoka Cancer Center (J2020-36) and with the 1964 Helsinki declaration ant its later amendments or with comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained in the form of opt-out on the website and bulletin board of our hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All authors declare neither financial interests that is relevant to the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors have no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}